P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR

• J. Mascarenhas,
• C. N. Harrison,
• J.-J. Kiladjian,
• R. S. Komrokji,
• S. Koschmieder,
• A. M. Vannucchi,
• T. Berry,
• D. Redding,
• L. Sherman,
• S. Dougherty,
• L. Peng,
• L. Sun,
• F. Huang,
• Y. Wan,
• F. M. Feller,
• A. Rizo,
• S. Verstovsek

Affiliations

J. Mascarenhas

1 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America

C. N. Harrison

2 Guy’s and St Thomas’ Hospital, London, United Kingdom

J.-J. Kiladjian

3 Hôpital Saint-Louis, Université Paris, Paris, France

R. S. Komrokji

4 H Lee Moffitt Cancer Center, Tampa, FL, United States of America

S. Koschmieder

5 RWTH Aachen University, Aachen, Germany

A. M. Vannucchi

6 AOU Careggi, University of Florence, Florence, Italy

T. Berry

7 Geron Corporation, Parsippany, NJ

D. Redding

7 Geron Corporation, Parsippany, NJ

L. Sherman

7 Geron Corporation, Parsippany, NJ

S. Dougherty

7 Geron Corporation, Parsippany, NJ

L. Peng

7 Geron Corporation, Parsippany, NJ

L. Sun

7 Geron Corporation, Parsippany, NJ

F. Huang

7 Geron Corporation, Parsippany, NJ

Y. Wan

7 Geron Corporation, Parsippany, NJ

F. M. Feller

7 Geron Corporation, Parsippany, NJ

A. Rizo

7 Geron Corporation, Parsippany, NJ

S. Verstovsek

8 The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America